• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Impel announces “streamlining plan,” halts development of INP105 intranasal olanzapine

Impel Pharmaceuticals announced that it will cut 16% of its workforce and halt development of INP105 intranasal olanzapine for the treatment of agitation in autism spectrum disorder. The company also said that its Chief Medical Officer, Stephen Shrewsbury, will be leaving Impel at the end of March.

According to the company, the move will allow the company to “reprioritize spend to capitalize on the continued positive momentum in payor and prescriber uptake of Trudhesa.” The FDA approved Trudhesa dihydroergotamine nasal spray for the treatment of migraine in 2021. Impel said that quarterly prescriptions of Trudhesa were up 58% from the second quarter to the fourth quarter of 2022, and totaled 58,424 for that year, with refill rates averaging 63% and reimbursement at more than 60%.

Impel Chairman of the Board and CEO Adrian Adams said, “Today’s announcement is part of a measured effort aimed at best positioning Impel to achieve its business objectives by streamlining clinical development expenses in order to focus resources on maximizing the growing commercial potential of Trudhesa.”

Adams added, “I would like to thank Dr. Shrewsbury for his contributions to Impel and, more broadly, for helping increase our understanding of the upper nasal space and positively changing expectations about the therapeutic potential of nasally administered medicines. Dr. Shrewsbury, along with the team under his leadership, played a pivotal role in developing the company’s proprietary Precision Olfactory Delivery (POD) technology and conducting the clinical development that led to the successful first-cycle approval of Trudhesa by the FDA.”

Read the Impel Pharmaceuticals press release.

Share

published on February 23, 2023

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Aptar Pharma banner
    © 2025 OINDPnews